分享产品介绍 评论(0)
物种
Canine, Feline分子别名
Beta-nerve growth factor, Beta-NGFAccession
A0A8I3PYI3表达序列
Ser122-Gly241
表达宿主
E.coli分子量
12-13 kDa (Non-Reducing)
纯度
>95% by SDS-PAGE.内毒素含量
<0.1EU/μg活性
EC50 = 1.1-1.4 ng/ml标记
Unconjugated标签
No Tag性状
Lyophilized Powder缓冲体系
PBS, pH7.4
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.文献引用
Animals (Basel). 2025 Nov 8;15(22):3243.
J Vet Intern Med. 2021 Nov 1;35(6):2752–2762.
β-NGF in dogs and cats shares the fundamental structure of a homodimeric neurotrophin essential for the development, maintenance, and survival of sensory and sympathetic neurons. NGF serves as a critical signaling molecule for pain and inflammation in veterinary species. In pathological conditions, NGF is widely implicated in peripheral and central sensitization mechanisms, significantly contributing to the genesis and maintenance of chronic pain.
β-NGF represents a critical therapeutic target in veterinary medicine, with species-specific anti-NGF monoclonal antibodies (bedinvetmab for dogs, frunevetmab for cats) representing the first major class of biologics approved for chronic pain management in companion animals. The development of these therapeutics exemplifies successful translational medicine, leveraging naturally occurring OA in dogs and cats as models for human disease while addressing unmet needs in veterinary pain management. The distinct safety profiles between species highlight the importance of species-specific antibody development and ongoing pharmacovigilance monitoring.
生物活性
Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. The EC50 for this effect is 1.1-1.4 ng/ml.
电泳
2μg (R: reducing condition, N: non-reducing condition).
评论(0)